Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practit

AbstractThe impact of breast cancer-related lymphedema (BCRL) on long-term quality of life is unknown. The aim of this study was to investigate the impact of BCRL on health-related quality of life (HRQoL) up to 10 years after breast cancer treatment. This regional population-based study enrolled patients treated for breast cancer with axillary lymph node dissection between January 1st 2007 and December 31th 2017. Follow up and assessments of the included patients were conducted between January 2019 and May 2020. The study outcome was HRQoL, evaluated with the Lymphedema Functioning, Disability and Health Questionnaire, the Disabilities of the Arm, Shoulder and Hand Questionnaire and the Short Form (36) Health Survey Questionnaire. Multivariate linear logistic regression models adjusted for confounders provided mean score differences (MDs) with 95% confidence intervals in each HRQoL scale and item. This study enrolled 244 patients with BCRL and 823 patients without BCRL. Patients with BCRL had significantly poorer HRQoL than patients without BCRL in 16 out of 18 HRQoL subscales, for example, in physical function (MDs 27, 95%CI: 24; 30), mental health (MDs 24, 95%CI: 21; 27) and social role functioning (MDs 20, 95%CI: 17; 23). Age, BMI, BCRL severity, hand and dominant arm affection had only minor impact on HRQoL (MDs < 5), suggesting a high degree of inter-individual variation in coping with lymphedema. This study showed that BCRL is associated with long-term impairments in HRQoL, especially affecting the physical and psychosocial domains. Surprisingly, BCRL diagnosis rather than clinical severity drove the largest impairments in HRQoL.

Download Full-text

Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

British Journal of Dermatology ◽

10.1111/bjd.19751 ◽

2021 ◽

Author(s):

K.S. Thomas ◽

C.A. Apfelbacher ◽

J.R. Chalmers ◽

E. Simpson ◽

P.I. Spuls ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Eczema ◽

Consensus Meeting ◽

Core Outcome ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Download Full-text

Health-related quality of life and long-term mortality in young and middle-aged hemodialysis patients

International Urology and Nephrology ◽

10.1007/s11255-021-02894-8 ◽

2021 ◽

Author(s):

Vladimir A. Dobronravov ◽

Irina A. Vasilieva

Keyword(s):

Quality Of Life ◽

Hemodialysis Patients ◽

Health Related Quality ◽

Middle Aged ◽

Related Quality ◽

Health Related ◽

Long Term Mortality

Download Full-text

Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting

European Neurology ◽

10.1159/000514828 ◽

2021 ◽

pp. 1-6

Author(s):

Cihat Uzunköprü ◽

Yesim Beckmann ◽

Sabiha Türe

Keyword(s):

Quality Of Life ◽

Multiple Sclerosis ◽

Real Life ◽

Life Assessment ◽

Health Related Quality ◽

Serious Adverse Events ◽

Related Quality ◽

Health Related

Introduction: The primary aim of the present study was to evaluate the long-term efficacy of fingolimod in patients with multiple sclerosis (MS); secondary aims were to describe the safety of fingolimod with the evaluation of treatment satisfaction and impact on the quality of life in real life. Methods: We collected clinical, demographical, neuroradiological, and treatment data, including pre- and posttreatment status health-related quality of life from 286 MS patients consecutively treated with fingolimod. Clinical assessment was based on the Expanded Disability Status Scale (EDSS), and quality of life assessment was performed with MS-related quality of life inventory (MSQOLI). The data were recorded at baseline and every 6 months for 2 years. Results: One hundred and fourteen males and 172 females were enrolled. The annualized relapse rate and EDSS showed a statistically significant reduction during the observation period (p < 0.001). The patients also demonstrated substantial improvements in magnetic resonance imaging (MRI) outcomes (p < 0.001). Health-related quality of life scores improved significantly between baseline and 24-month visit (p < 0.001). No serious adverse events occurred. Conclusion: In our cohort, fingolimod treatment was associated with reduced relapse, MRI activity, and improved EDSS and MSQOLI scores. Additionally, fingolimod has been able to maintain its effectiveness over a considerable long period of treatment.

Download Full-text

Impact of malnutrition on health-related quality of life in persons receiving dialysis: a prospective study

British Journal Of Nutrition ◽

10.1017/s000711452100249x ◽

2021 ◽

pp. 1-24

Author(s):

Daniela Viramontes-Hörner ◽

Zoe Pittman ◽

Nicholas M Selby ◽

Maarten W Taal

Keyword(s):

Quality Of Life ◽

Prospective Study ◽

Health Related Quality ◽

Poor Hrqol ◽

Sf 36 ◽

Related Quality ◽

Health Related ◽

The Impact ◽

Over Time

Abstract Health-related quality of life (HRQoL) is severely impaired in persons receiving dialysis. Malnutrition has been associated with some measures of poor HRQoL in cross-sectional analyses in dialysis populations, but no studies have assessed the impact of malnutrition and dietary intake on change in multiple measures of HRQoL over time. We investigated the most important determinants of poor HRQoL and the predictors of change in HRQoL over time using several measures of HRQoL. We enrolled 119 haemodialysis and 31 peritoneal dialysis patients in this prospective study. Nutritional assessments (Subjective Global Assessment [SGA], anthropometry and 24-hour dietary recalls) and HRQoL questionnaires (Short Form-36 [SF-36] mental [MCS] and physical component scores [PCS] and European QoL-5 Dimensions [EQ5D] health state [HSS] and visual analogue scores [VAS]) were performed at baseline, 6 and 12 months. Mean age was 64(14) years. Malnutrition was present in 37% of the population. At baseline, malnutrition assessed by SGA was the only factor independently (and negatively) associated with all four measures of HRQoL. No single factor was independently associated with decrease in all measures of HRQoL over 1 year. However, prevalence/development of malnutrition over one year was an independent predictor of 1-year decrease in EQ5D HSS and 1-year decrease in fat intake independently predicted the 1-year decline in SF-36 MCS and PCS, and EQ5D VAS. These findings strengthen the importance of monitoring for malnutrition and providing nutritional advice to all persons on dialysis. Future studies are needed to evaluate the impact of nutritional interventions on HRQoL and other long-term outcomes.

Download Full-text